# EDGAR Filing Document

**Accession Number:** 0001541157
**File Stem:** 0001493152-26-024741
**Filing Date:** 2026-5
**Character Count:** 3397
**Document Hash:** 2832ae285b8c724e4e7a02a7906ae79b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-024741.hdr.sgml**: 20260521

**ACCESSION NUMBER**: 0001493152-26-024741

**CONFORMED SUBMISSION TYPE**: RW

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260521

**DATE AS OF CHANGE**: 20260521

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akari Therapeutics Plc
- **CENTRAL INDEX KEY:** 0001541157
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981034922
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** RW

**SEC ACT:**
- **SEC FILE NUMBER:** 333-295729
- **FILM NUMBER:** 261005946

**BUSINESS ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602
- **BUSINESS PHONE:** (929) 274-7510

**MAIL ADDRESS:**
- **STREET 1:** 401 EAST JACKSON STREET
- **STREET 2:** SUITE 3300
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celsus Therapeutics Plc.
- **DATE OF NAME CHANGE:** 20130621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Morria Biopharmaceuticals PLC
- **DATE OF NAME CHANGE:** 20120201

**Akari Therapeutics, Plc**

401 East Jackson Street, Suite 3300

Tampa, FL 33602

May 20, 2026

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Akari Therapeutics, Plc** |
|  | **Request to Withdraw Draft Registration Statement on Form S-1** |
|  | **Filed May 8, 2026** |
|  | **File No. 333-295729** |

---

Ladies and Gentlemen:

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the "**Securities Act**"), Akari Therapeutics, Plc (the "**Company**") hereby respectfully requests that the Securities and Exchange Commission (the "**Commission**") consent to the withdrawal of the Company's Registration Statement on Form S-1 (File No. 333-295729), together with all exhibits thereto (collectively, the "**Registration Statement**"), effective as of the date hereof or at the earliest practicable date thereafter. The Registration Statement was filed with the Commission on May 8, 2026.

The Company is requesting withdrawal of the Registration Statement because it does not intend to pursue the contemplated public offering of the securities covered thereby at this time. The Registration Statement has not been declared effective by the Commission, and no securities have been issued or sold pursuant to the Registration Statement. Accordingly, the Company believes that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by Rule 477(a) under the Securities Act.

In accordance with Rule 457(p) under the Securities Act, the Company respectfully requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use by the Company.

Please direct any questions or comments regarding this request to the undersigned.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **AKARI THERAPEUTICS, PLC** | **AKARI THERAPEUTICS, PLC** |
| By: | */s/ Abizer Gaslightwala* |
| Name: | Abizer Gaslightwala |
| Title: | President and Chief Executive Officer |

---